Management of polypharmacy and potential drug-drug interactions in people with HIV and cancer: insights from a 4-year multidisciplinary clinic experience
A high prevalence of polypharmacy and clinically relevant DDIs was observed in our cohort of PWHC. A multidisciplinary team could play a pivotal role in optimizing pharmacological therapies in this clinical setting, for example, by reducing the use of PPIs and booster-based antiretroviral regimens.
Authors
- Andrea Gori (ORCID: https://orcid.org/0000-0003-0931-0454)
- Spinello Antinori (ORCID: https://orcid.org/0000-0003-0569-9407)
- Andrea Giacomelli (ORCID: https://orcid.org/0000-0003-3685-4289)
- Alberto Dolci (ORCID: https://orcid.org/0000-0002-9833-7538)
- Nicla La Verde (ORCID: https://orcid.org/0000-0002-2884-1632)
- Cinzia Fasola
- Lorenzo Ruggieri (ORCID: https://orcid.org/0000-0002-9972-2761)
- Anna Lisa Ridolfo (ORCID: https://orcid.org/0000-0003-1106-6219)
- C Pruneri
- Maria Vittoria Cossu (ORCID: https://orcid.org/0000-0002-6984-3028)
- Davide Dalu
- Dario Cattaneo (ORCID: https://orcid.org/0000-0003-1512-6530)
- Cristina Gervasoni (ORCID: https://orcid.org/0000-0002-4922-6495)
- Aurora Civati
Institutions
- University of Milan (IT)
- Luigi Sacco Hospital (IT)
- ASST Fatebenefratelli Sacco (IT)
Publication Details
- Journal
- Expert Opinion on Drug Metabolism & Toxicology
- Published
- 2025-04-05
- DOI
- https://doi.org/10.1080/17425255.2025.2489393
- Citations
- 1
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.22